接受治疗的人类免疫缺陷病毒感染者中无加速衰老相关脑病理的证据:艾滋病合并症(COBRA)项目纵向神经影像结果
多中心纵向研究纳入134例病毒学抑制的HIV感染者(中位年龄56.0岁)和79例人口学相似的HIV阴性对照(中位年龄57.2岁),在基线及2年时进行神经心理评估和多模态神经影像。结果显示基线时感染者整体认知表现更差(P < .01)、灰质体积更低(P = .04)、白质高信号负荷更高(P = .02)、白质微结构异常(P < .005)及脑预测年龄差更大(P = .01),但纵向2年内任何神经影像指标变化率均无显著组间差异(P > .1),认知表现稳定。结论认为接受成功治疗的中年HIV感染者无加速衰老相关脑改变或认知下降证据。
要点
- 基线时HIV感染者整体认知表现更差(P < .01)、灰质体积更低(P = .04)、白质高信号负荷更高(P = .02)。
- 基线时HIV感染者白质微结构异常(P < .005)且脑预测年龄差更大(P = .01)。
- 纵向2年内任何神经影像指标变化率均无显著组间差异(P > .1),两组认知表现稳定。
核心结论
- 接受成功治疗的中年HIV感染者在2年内无加速衰老相关脑改变或认知下降的证据。
研究设计与样本
- 多中心纵向研究纳入134例病毒学抑制的HIV感染者(中位年龄56.0岁)和79例人口学相似的HIV阴性对照(中位年龄57.2岁)。
- 在基线及2年时进行详细神经心理评估和多模态神经影像(T1加权、T2加权、扩散磁共振成像、静息态功能磁共振、波谱、动脉自旋标记)。
- 采用线性混合效应模型评估组间变化率差异。
主要发现
- 123例HIV感染者和78例HIV阴性对照完成纵向评估(中位间隔1.97年)。
- 两组在年龄、性别、受教育年限、吸烟或饮酒方面无差异。
- 基线时HIV感染者整体认知表现更差(P < .01)、灰质体积更低(P = .04)、白质高信号负荷更高(P = .02)、白质微结构异常(P < .005)及脑预测年龄差更大(P = .01)。
- 纵向任何神经影像指标变化率均无显著组间差异(P > .1),两组认知表现纵向稳定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite successful antiretroviral therapy, people living with human immunodeficiency virus (PLWH) experience higher rates of age-related morbidity, including abnormal brain structure, brain function, and cognitive impairment. This has raised concerns that PLWH may experience accelerated aging-related brain pathology. METHODS: We performed a multicenter longitudinal study of 134 virologically suppressed PLWH (median age, 56.0 years) and 79 demographically similar human immunodeficiency virus (HIV)-negative controls (median age, 57.2 years). To measure cognitive performance and brain pathology, we conducted detailed neuropsychological assessments and multimodality neuroimaging (T1-weighted, T2-weighted, diffusion magnetic resonance imaging [MRI], resting-state functional MRI, spectroscopy, arterial spin labeling) at baseline and at 2 years. Group differences in rates of change were assessed using linear mixed effects models. RESULTS: One hundred twenty-three PLWH and 78 HIV-negative controls completed longitudinal assessments (median interval, 1.97 years). There were no differences between PLWH and HIV-negative controls in age, sex, years of education, smoking or alcohol use. At baseline, PLWH had poorer global cognitive performance (P < .01), lower gray matter volume (P = .04), higher white matter hyperintensity load (P = .02), abnormal white matter microstructure (P < .005), and greater brain-predicted age difference (P = .01). Longitudinally, there were no significant differences in rates of change in any neuroimaging measure between PLWH and HIV-negative controls (P > .1). Cognitive performance was longitudinally stable in both groups. CONCLUSIONS: We found no evidence that middle-aged PLWH, when receiving successful treatment, are at increased risk of accelerated aging-related brain changes or cognitive decline over 2 years.
引用
- Cole JH, Caan MWA, Underwood J, et al. No Evidence for Accelerated Aging-Related Brain Pathology in Treated Human Immunodeficiency Virus: Longitudinal Neuroimaging Results From the Comorbidity in Relation to AIDS (COBRA) Project. Clin Infect Dis. 2018. PMID: 29309532. doi:10.1093/cid/cix1124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。